Zolpidem, zaleplon, and eszopiclone are grouped together because they:
Choose an answer, then check it.
Clinical Pharmacology · Sedatives and Anxiolytics
Nonbenzodiazepine Hypnotics
On this page 6 sections
In 30 seconds
Nonbenzodiazepine hypnotics are sleep-promoting drugs that are not chemically benzodiazepines but often act on the same receptor system or a completely different one. The main groups are the "Z-drugs" (zolpidem, zaleplon, eszopiclone), the melatonin receptor agonist ramelteon, the orexin receptor antagonists (suvorexant, lemborexant), and sedating antihistamines or low-dose doxepin. They matter because prescribers reach for them when insomnia needs short-term drug treatment, but every class carries real risks — including a boxed warning for complex sleep behaviors — and none replaces sleep hygiene or cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment.
The college version
Z-drugs: selective GABA-A modulators
Zolpidem, zaleplon, and eszopiclone bind the same benzodiazepine-recognition site on the GABA-A receptor complex as benzodiazepines, enhancing chloride channel opening and neuronal inhibition. Structurally they are unrelated compounds, but pharmacologically they show relative selectivity for the alpha-1 GABA-A subunit, most associated with sedation rather than anxiolysis or muscle relaxation. This is why they are marketed almost exclusively as hypnotics rather than general anxiolytics. Zaleplon has a very short half-life and suits sleep-onset difficulty or middle-of-the-night dosing when enough sleep time remains; zolpidem treats sleep-onset problems and, in extended-release form, sleep maintenance; eszopiclone's longer duration suits maintenance. A key pharmacokinetic principle: women metabolize zolpidem more slowly than men on average, producing higher morning blood levels for the same amount — the basis for sex-specific dosing considerations in principle.
Melatonin receptor agonists
Ramelteon agonizes melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus, reinforcing the body's endogenous circadian sleep-wake signal rather than directly sedating the brain via GABA. It targets sleep-onset insomnia and carries lower dependence and abuse potential than GABAergic hypnotics because it does not act at the benzodiazepine site.
Orexin receptor antagonists
Suvorexant and lemborexant block orexin (hypocretin) receptors, dampening the wake-promoting orexin system rather than boosting an inhibitory one. Orexin neurons normally sustain wakefulness and arousal; antagonizing this pathway lets sleep emerge more naturally. This mechanism is newer than GABAergic approaches and treats sleep-onset or sleep-maintenance difficulty.
Sedating antihistamines and low-dose doxepin
Over-the-counter sedating antihistamines (H1 antagonists such as diphenhydramine) are widely used for occasional sleeplessness, but tolerance develops quickly and anticholinergic effects (dry mouth, constipation, urinary retention, confusion) make them poor choices for older adults. Doxepin, a tricyclic antidepressant, is repurposed at low dose as a selective H1 antagonist for sleep maintenance insomnia, without the anticholinergic burden seen at antidepressant doses.
Adverse effects and safety framing
All hypnotics share concerns about next-morning residual sedation, psychomotor and cognitive impairment (relevant to driving), and fall risk in older adults, who are more sensitive to CNS depressants generally. Z-drugs carry a boxed warning for complex sleep behaviors — sleepwalking, sleep-driving, sleep-eating, and other activities performed with no memory of them (anterograde amnesia) — that can occur even at recommended use and warrant discontinuation if they occur. Dependence and rebound insomnia on discontinuation are possible with GABAergic agents, though generally less pronounced than with benzodiazepines. Because of these risks, and because hypnotics treat symptoms rather than causes, guidelines frame drug therapy as a short-term bridge, with sleep hygiene and CBT-I recommended as first-line, more durable interventions.
Nursing considerations
Administer hypnotics immediately before the intended sleep period, only when the patient has a full uninterrupted night (about 7-8 hours) available, since waking early risks residual impairment and unsafe activity. Assess fall risk and orient environments accordingly, especially in older adults, and counsel patients about the possibility of complex sleep behaviors and the need to avoid combining these drugs with alcohol or other CNS depressants.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Think of your brain at night like a house with a "wake-up light switch" and a "quiet-down dimmer." Some sleep medicines turn the dimmer down (Z-drugs), some talk directly to your body's built-in nighttime clock (ramelteon), and some just flip off the wake-up switch instead of dimming anything (suvorexant, lemborexant). All of them help you fall or stay asleep, but none fix why you're not sleeping in the first place — that's more like learning better bedtime habits (CBT-I), which works better long-term. And because these medicines mess with your brain, doctors want you to take them only right before bed, with a whole night free, because weird things can happen — like walking around or eating without remembering it — if you don't get enough sleep afterward.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A nurse is teaching a patient newly prescribed a Z-drug for insomnia. What two pieces of timing/safety guidance should the nurse emphasize regarding when and how to take the medication?
Show answer
Take the medication immediately before getting into bed, not earlier while still doing other tasks, and only when a full night of uninterrupted sleep (about 7-8 hours) is actually available, since waking too soon risks impaired coordination, memory gaps, or unsafe complex sleep behavior.
Explain why CBT-I and sleep hygiene are considered first-line for chronic insomnia even though hypnotic drugs are available and effective.
Show answer
Hypnotic drugs treat the symptom of not sleeping but don't fix the habits, thoughts, or routines causing poor sleep, and they carry risks like dependence, morning grogginess, falls, and complex sleep behaviors with continued use. CBT-I addresses the underlying patterns driving insomnia, producing more durable improvement without those drug-related risks.
Quick check
3 questions here. Answers stay hidden until you check.
Which hypnotic class works by antagonizing a wake-promoting neuropeptide system rather than enhancing an inhibitory one?
Choose an answer, then check it.
Which adverse effect carries a boxed warning specifically associated with Z-drugs?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.